

Product Name: Terazosin hydrochloride

Catalog No.: 1506


Batch No.: 2

CAS Number: 63074-08-8

IUPAC Name: 1-(4-Amino-6,7-dimethoxy-2-quinazoliny)-4-[(tetrahydro-2-furanyl)carbonyl]-piperazine hydrochloride

1. PHYSICAL AND CHEMICAL PROPERTIES

Batch Molecular Formula: C₁₉H₂₅N₅O₄.HCl.1³/₄H₂O
Batch Molecular Weight: 455.42
Physical Appearance: White solid
Solubility: water to 20 mM with gentle warming
Storage: Store at RT
Batch Molecular Structure:



2. ANALYTICAL DATA

HPLC: Shows 99.1% purity
¹H NMR: Consistent with structure
Mass Spectrum: Consistent with structure

Microanalysis:

| | Carbon | Hydrogen | Nitrogen | Chlorine |
|-------------|--------|----------|----------|----------|
| Theoretical | 50.11 | 6.53 | 15.38 | 7.78 |
| Found | 49.49 | 6.63 | 15.13 | 7.54 |

Caution - Not Fully Tested • Research Use Only • Not For Human or Veterinary Use

Product Name: Terazosin hydrochloride

Catalog No.: 1506

2

CAS Number: 63074-08-8

IUPAC Name: 1-(4-Amino-6,7-dimethoxy-2-quinazoliny)-4-[(tetrahydro-2-furanyl)carbonyl]-piperazine hydrochloride

Description:

Terazosin hydrochloride is a selective α_1 antagonist. Increases phosphoglycerate kinase 1 (PGK1) activity ($K_d = 2.9 \mu\text{M}$). Upregulates glucose metabolism and increases ATP production. In an in vitro model of GI disease, terazosin reduces inflammation and protects against oxidative damage. Neuroprotective in in vivo models of ALS and Parkinson's Disease. Antihypertensive following oral or intravenous administration in vivo.

Physical and Chemical Properties:


Batch Molecular Formula: $\text{C}_{19}\text{H}_{25}\text{N}_5\text{O}_4 \cdot \text{HCl} \cdot 1\frac{1}{4}\text{H}_2\text{O}$

Batch Molecular Weight: 455.42

Physical Appearance: White solid

Minimum Purity: $\geq 98\%$

Batch Molecular Structure:



Storage: Store at RT

Solubility & Usage Info:

water to 20 mM with gentle warming

Stability and Solubility Advice:

Some solutions can be difficult to obtain and can be encouraged by rapid stirring, sonication or gentle warming (in a 45-60°C water bath).

Information concerning product stability, particularly in solution, has rarely been reported and in most cases we can only offer a general guide. *Unless contradicted by product-specific protocols or instructions, our standard recommendations apply:

SOLIDS: Provided storage is as stated on the product label and the vial is kept tightly sealed, the product can be stored for up to 6 months from date of receipt.

SOLUTIONS: We recommend that stock solutions, once prepared, are stored aliquoted in tightly sealed vials at -20°C or below and used within 1 month. Wherever possible solutions should be made up and used on the same day.

References:

Hancock et al (1995) Actions of tera. and its enantiomers at subtypes of α_1 - and α_2 -adrenoceptors *in vitro*. J.Recept.Signal Transduct.Res. **15** 863. PMID: 8673721.

Maruyama et al (1994) Comparison of displacemental potencies of tera. enantiomers for α_1 -adrenoceptor subtypes. Biol.Pharm.Bull. **17** 1126. PMID: 7820122.

Kyncl (1986) Pharmacology of tera. Am.J.Med. **80** 12. PMID: 2872801.

Caution - Not Fully Tested • Research Use Only • Not For Human or Veterinary Use

bio-techne.com

info@bio-techne.com
techsupport@bio-techne.com

North America

Tel: (800) 343 7475

China

info.cn@bio-techne.com
Tel: +86 (21) 52380373

Europe Middle East Africa

Tel: +44 (0)1235 529449

Rest of World

www.tocris.com/distributors
Tel:+1 612 379 2956